ADULT patients living with schizophrenia will be able to access Reagila (cariprazine) through the Pharmaceutical Benefits Scheme (PBS), following its listing on 01 Sep.
Mental Illness Fellowship of Australia (MIFA) CEO, Tony Stevenson, welcomed the reimbursement of a new treatment option for those living with schizophrenia.
"The availability and accessibility of affordable treatment options for adults living with schizophrenia is crucial for this patient community, given the stigma they experience with the disorder, and resulting social isolation," he said.
Stevenson added that delays in accessing treatment places patients at higher risk of a more severe course of illness.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Sep 21
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Sep 21
